Management of post-menopausal osteoporosis in leprosy patients using one-monthly oral Ibandronate administration

Shailesh Nagpure, Ranjana Kale, Swanand Pathak, Satyavan Patel

Abstract


Objective: To study the effects of once monthly regimen of Ibandronate on bone marrow density, severity of osteoporosis and quality of life in postmenopausal osteoporotic leprosy patients.

Materials and Methods: Out of 204 eligible participants, written consent was given by 200 participants who were hence enrolled for the study. These 200 patients with postmenopausal osteoporotic leprosy were administered with Ibandronate tablet (150mg) as once monthly from October 2010 to October 2011. Patients were analyzed for BMD, severity of osteoporosis and quality of life index.

Results: The percentage change in the hip BMD at first follow up was increased by 8.83%. and with second follow up it was increased by 14.51%. A total of 4 patients were in Singh’s Index Grade I, 128 patients in Grade II and 60 patients in Grade III severity at the baseline screening. No study dropouts were found for entire 1 year of treatment duration, that is 100% adherence were observed in subjects undergoing treatment.

Conclusion: Monthly regimen of Ibandronate confirmed having better tolerability and adherence in postmenopausal osteoporotic leprosy patients. The present study was grounded on the assumption that osteoporotic postmenopausal leprosy patients often experience low levels of quality of life. This was substantiated by the findings, where majority of females in showed improvement in their QOL, with reference to physical activity and pain, limitations to daily activities, change in emotional status and general health status.


Keywords


post-menopausal, leprosy, osteoporosis, Ibandronate

Full Text:

PDF

References


. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy, March 7- 29, 2000: highlights of the conference. South Med J. 2001; 94(6):569-573.

. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002; 359: 2018-2026.

. Natasha J, Maurice B, Eithne M. Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Interv Aging. 2006; 1(4):377-387.

. Moonot P, Ashwood N, Lockwood D. Orthopedic complications of Leprosy. J Bone Joint Surg [Br]. 2005; 87: 1328-1332.

. Ishikawa S, Ishikawa A, Yoh K, Tanaka H, Fujiwara M. Osteoporosis in male and female leprosy patients. Calcif Tissue Int. 1999; 64:144–147.

. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med. 2006; 119 (Suppl.1): S18-24.

. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119 (Suppl. 1):12-7.

. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19:1241–1249.

. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc. 2005; 80:379–388.

. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282:1344–1352.

. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333:1437–1443.

. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005; 20:1315–1322.

. Bartl R, Goette S, Hadji P, Hammerschmidt T. Persistence and compliance with daily and weekly administered bisphophonates for osteoporosis treatment in Germany. Osteoporos Int. 2005; 16 Suppl 3: S45.

. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women. J Bone Miner Res. 2004;19: S448

. Ettinger MP, Gallagher R, Amonkar M, Mahoney PM, Gilbride J. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum. 2004; 50: S513

. Jun Iwamoto. Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis. Yonsei Med J. 2008; 49(1): 119-128.

. Akan K, Cift H, Ozkan K. Osteoporosis and clinical outcomes in itertrochantric hip fractures. J Int Med Res. 2011; 39: 857-865.

. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.

. Badia X, Diez P, Lahoz R. The ECOS-16 Questionnaire for the evaluation of health-related quality of life in elderly with osteoporosis. Health Quality Life Outcomes. 2004; 2: 41.

. Badia X, Díez-Pérez A, Alvarez-Sanz C, Díaz-López B, Díaz-Curiel M, Guillén F. Spanish GRECO Study Group, Measuring quality of life in women with vertebral fractures due to osteoporosis. A comparison of the OQLQ and QUALEFFO. Qual Life Res. 2001; 10:307-317.

. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yanagimoto K, Sakota K. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007; 25:302–309.

. Van Beck E, Lowik C, Que I. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl group with an amino group. J Bone Miner Res. 1996; 11:1492–1497.

. Ebetino FH, Francis MD, Rogers MJ. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharm. 1998; 9:233–243.




DOI: http://dx.doi.org/10.7439/ijbr.v8i11.4468

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 International Journal of Biomedical and Advance Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)